Natco Pharma Limited has informed the Exchange regarding a press release dated October 31, 2025, titled "NATCO announces launch of its Everolimus tablets, 1 mg, (generic of Zortress®)".
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma has announced the launch of its generic Everolimus tablets in 1 mg strength, which is the generic equivalent of Zortress®. Everolimus is an immunosuppressant used to prevent organ rejection in kidney and liver transplant patients. The launch expands Natco's generic product portfolio and allows it to enter a niche but steady specialty pharma segment. As a generic version, it will be priced lower than the branded counterpart, potentially helping Natco capture market share. This is part of Natco's ongoing strategy to grow its US and specialty generics business.
Positive for the company's specialty generics pipeline and long-term revenue diversification, though the niche size of the 1 mg segment may limit immediate financial impact. Shareholders may view this as steady portfolio expansion rather than a major catalyst.